With Novartis Ending RNAi Research Partnership, Alnylam Trims Workforce
This article was originally published in The Pink Sheet Daily
In ending the five-year collaboration, Novartis said it will work to develop RNAi therapeutics against 31 targets, which could bring Alnylam significant milestones down the road.
You may also be interested in...
The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.
Roche paying $450 million for Danish biotech Santaris is likely to fuel excitement around RNA-targeting technologies and may generate a liquidity boost for Europe’s VC sector.
Suit alleges Alnylam stole Tekmira's RNAi delivery technology, but Alnylam dismisses the claims and says its delivery technology falls within its licensing agreement or other partnerships.